FibroGen Announces Non-Dilutive Term Loan Financing for up to $150 Million with Morgan Stanley Tactical Value
May 01, 2023 07:00 ET
|
FibroGen, Inc.
Strengthens balance sheet with significant non-dilutive capital Aligned to support FibroGen operational plan Allows for the continued advancement of pamrevlumab, as well as our pre-clinical...
FibroGen to Report First Quarter 2023 Financial Results
April 24, 2023 07:00 ET
|
FibroGen, Inc.
SAN FRANCISCO, April 24, 2023 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) will announce its first quarter 2023 financial results on Monday, May 8 after the market close. FibroGen will also...
FibroGen Announces Completion of Patient Enrollment in ZEPHYRUS-2, a Phase 3 Clinical Study of Pamrevlumab in Idiopathic Pulmonary Fibrosis
April 03, 2023 07:00 ET
|
FibroGen, Inc.
- 372 IPF Patients Enrolled -- Topline Data Anticipated Mid-2024 - SAN FRANCISCO, April 03, 2023 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced the completion of patient...
FibroGen Reports Fourth Quarter and Full Year 2022 Financial Results
February 27, 2023 16:01 ET
|
FibroGen, Inc.
Topline Data from Five Pivotal Phase 3 Trials in 2023Total Company Revenue $140.7 Million in 2022Continued Strong Roxadustat Volume Growth in China SAN FRANCISCO, Feb. 27, 2023 (GLOBE NEWSWIRE) --...
FibroGen to Present at Cowen’s 43rd Annual Health Care Conference
February 27, 2023 07:00 ET
|
FibroGen, Inc.
SAN FRANCISCO, Feb. 27, 2023 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that Mark Eisner, M.D., M.P.H., Chief Medical Officer, will participate in a panel discussion at...
FibroGen to Report Fourth Quarter and Full Year 2022 Financial Results
February 17, 2023 07:00 ET
|
FibroGen, Inc.
SAN FRANCISCO, Feb. 17, 2023 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) will announce its fourth quarter and full year 2022 financial results on Monday, February 27 after the market close....
FibroGen to Present at SVB Securities Global Biopharma Conference
February 02, 2023 07:00 ET
|
FibroGen, Inc.
SAN FRANCISCO, Feb. 02, 2023 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that Enrique Conterno, Chief Executive Officer, will participate in a virtual fireside chat at the SVB...
FibroGen to Participate at Bank of America 2022 Biotech SMID Cap Virtual Conference
November 28, 2022 07:00 ET
|
FibroGen, Inc.
SAN FRANCISCO, Nov. 28, 2022 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that Enrique Conterno, Chief Executive Officer, will participate in a fireside chat at the Bank of...
FibroGen Reports Third Quarter 2022 Financial Results
November 07, 2022 16:01 ET
|
FibroGen, Inc.
Continued advancement of pamrevlumab clinical trials – topline data from five pivotal Phase 3 trials beginning in 1H 2023 through mid-2024Completed enrollment of MATTERHORN Phase 3 study of roxadustat...
FibroGen Announces $50 Million Royalty Monetization Financing with NovaQuest Capital Management
November 07, 2022 16:00 ET
|
FibroGen, Inc.
Strengthens balance sheet with strategic non-dilutive capital to support strategic prioritiesSupported by global launches of EVRENZO™ in the territories partnered with Astellas Pharma Inc.FibroGen...